Home/Pipeline/BOOM-IBD2 Pivotal Trial

BOOM-IBD2 Pivotal Trial

Ulcerative Colitis (Inflammatory Bowel Disease)

PivotalActive

Key Facts

Indication
Ulcerative Colitis (Inflammatory Bowel Disease)
Phase
Pivotal
Status
Active
Company

About Boomerang Medical

Boomerang Medical is a clinical-stage medical device company pioneering a bioelectric neuromodulation therapy for autoimmune conditions, with an initial focus on Inflammatory Bowel Disease (IBD). Its lead technology has secured FDA Breakthrough Device Designation for Crohn's and ulcerative colitis and is currently being evaluated in an FDA-approved pivotal trial (BOOM-IBD2). The company is backed by leading venture capital firms, led by an experienced executive team with deep medtech expertise, and is positioned at the convergence of neurology and immunology within the emerging field of bioelectronic medicine.

View full company profile

Other Ulcerative Colitis (Inflammatory Bowel Disease) Drugs

DrugCompanyPhase
TP-317Thetis PharmaceuticalsPhase 1b